title: ▾Xiapex for Dupuytren's contracture.
abstract: Dupuytren's contracture is a benign, progressive disabling condition of the hands. Traditionally, surgery (e.g. fasciotomy, fasciectomy, joint fusion and amputation) has been the only effective treatment but it is not an option for every patient. A potential alternative intervention is a formulation of collagenase Clostridium histolyticum (▾Xiapex--Pfizer Limited), which has been licensed for injection directly into the affected joint as treatment for adults with Dupuytren's contracture.5 Here we review the evidence for collagenase C. histolyticum and discuss its place in the management of this condition.
mesh_terms: D000328:Adult; D047009:Hathewaya histolytica / Q000201:enzymology*; D016527:Drug Costs; D004387:Dupuytren Contracture / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D015552:Injections, Intralesional; D003012:Microbial Collagenase / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D003012:Microbial Collagenase